Pall's business is split into two broad groups: Life Sciences (c.51%) and Industrial (c.49%). In September 2022, it was announced that Pall Life Sciences will be merging with Cytiva to create a new Biotechnology Group within Danaher. In March 2026, Pall appointed Dr. Roland Folz as President, effective March 3, 2026.
Cyborg Score Rationale
Pall benefits from Danaher's backing as a wholly-owned subsidiary with scale advantages in life sciences and industrial markets. Recent leadership transition and ongoing capacity investments signal stability and growth focus. Strong positioning in high-growth bioprocessing and filtration segments, though private status limits full transparency.
Top Insights
(February 2026) Pall partnered with MTR Carbon Capture to advance carbon capture solutions, expanding into emerging environmental markets
(January 2024) Introduced SepraLYTE™ liquid/gas coalescers for green hydrogen production, demonstrating innovation in clean energy applications
Life Sciences and Industrial segments are balanced, with continued capacity expansion to meet pharmaceutical manufacturing demand
(March 2026) New president Dr. Roland Folz appointed, signaling strategic direction and operational focus under Danaher ownership
Named Competitors
Bioprocessing Systems — Bioprocess solutions and lab instruments
Bioprocess Chromatography — Bioprocessing technologies for pharmaceutical manufacturing
Industrial Filtration — Fluid handling solutions and equipment